Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)
- PMID: 27604375
- DOI: 10.1007/s00345-016-1928-x
Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)
Abstract
Purpose: Upper-tract urothelial carcinoma (UTUC) is a relatively uncommon disease with limited available evidence on specific topics. The purpose of this article was to review the previous literature to summarize the current knowledge about UTUC epidemiology, diagnosis, preoperative evaluation and prognostic assessment.
Methods: Using MEDLINE, a non-systematic review was performed including articles between January 2000 and February 2016. English language original articles, reviews and editorials were selected based on their clinical relevance.
Results: UTUC accounts for 5-10 % of all urothelial cancers, with an increasing incidence. UTUC and bladder cancer share some common risk factors, even if they are two different entities regarding practical, biological and clinical characteristics. Aristolochic acid plays an important role in UTUC pathogenesis in certain regions. It is further estimated that approximately 10 % of UTUC are part of the hereditary non-polyposis colorectal cancer spectrum disease. UTUC diagnosis remains mainly based on imaging and endoscopy, but development of new technologies is rapidly changing the diagnosis algorithm. To help the decision-making process regarding surgical treatment, extent of lymphadenectomy and selection of neoadjuvant systemic therapies, predictive tools based on preoperative patient and tumor characteristics have been developed.
Conclusions: Awareness regarding epidemiology, diagnosis, preoperative evaluation and prognostic assessment changes is essential to correctly diagnose and manage UTUC patients, thereby potentially improving their outcomes.
Keywords: Diagnosis; Epidemiology; New technologies; Predictive tools; Prognosis; Risk factor; UTUC.
Similar articles
-
Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma.World J Urol. 2017 Mar;35(3):355-365. doi: 10.1007/s00345-016-1859-6. Epub 2016 May 27. World J Urol. 2017. PMID: 27233780 Free PMC article. Review.
-
Secondary bladder cancer after upper tract urothelial carcinoma in the US population.BJU Int. 2012 Nov;110(9):1325-9. doi: 10.1111/j.1464-410X.2012.11108.x. Epub 2012 May 7. BJU Int. 2012. PMID: 22564365
-
Ureteroscopic management of upper tract urothelial carcinoma (UTUC) in patients with Lynch Syndrome (hereditary nonpolyposis colorectal cancer syndrome).BJU Int. 2013 Oct;112(6):813-9. doi: 10.1111/bju.12008. Epub 2013 Mar 1. BJU Int. 2013. PMID: 23452166
-
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update.Eur Urol. 2015 Nov;68(5):868-79. doi: 10.1016/j.eururo.2015.06.044. Epub 2015 Jul 16. Eur Urol. 2015. PMID: 26188393
-
Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease.World J Urol. 2017 Mar;35(3):327-335. doi: 10.1007/s00345-016-1819-1. Epub 2016 Apr 4. World J Urol. 2017. PMID: 27043218 Review.
Cited by
-
The use of endoscopic combined intrarenal surgery as an additional approach to upper urinary tract urothelial carcinoma: Our Experience.Indian J Urol. 2021 Apr-Jun;37(2):187-188. doi: 10.4103/iju.IJU_71_20. Epub 2021 Apr 1. Indian J Urol. 2021. PMID: 34103806 Free PMC article.
-
Cause of death during upper tract urothelial carcinoma survivorship: A contemporary, population-based analysis.Front Oncol. 2022 Oct 28;12:948289. doi: 10.3389/fonc.2022.948289. eCollection 2022. Front Oncol. 2022. PMID: 36387214 Free PMC article.
-
STAT3 and Its Pathways' Dysregulation-Underestimated Role in Urological Tumors.Cells. 2022 Sep 27;11(19):3024. doi: 10.3390/cells11193024. Cells. 2022. PMID: 36230984 Free PMC article. Review.
-
Upper Tract Urinary Carcinoma: A Unique Immuno-Molecular Entity and a Clinical Challenge in the Current Therapeutic Scenario.Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231159753. doi: 10.1177/15330338231159753. Technol Cancer Res Treat. 2023. PMID: 36855829 Free PMC article. Review.
-
Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study.J Immunother Cancer. 2022 May;10(5):e004427. doi: 10.1136/jitc-2021-004427. J Immunother Cancer. 2022. PMID: 35537782 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical